Zychrome™ brand chromium dinicocysteinate is a unique, patent-pending, next-generation chromium complex. Preliminary clinical data of a 90-day, randomized, double-blind, placebo-controlled study conducted in the United States showed that Zychrome™ may be twice as effective as chromium picolinate in supporting normal insulin sensitivity, activity and levels trending toward normal range.*
A recent survey of 374 diabetes educators attending the 2011 AADE Meeting & Exhibition revealed:
- Over 88% indicated that the statistically significant endpoints in Zychrome™ research support the conclusion that Zychrome™ is better than chromium picolinate for insulin management.
- Over 70% would recommend Zychrome™ for insulin management over chromium picolinate if available on the market.
Helpful Answers
Zychome™ brand chromium dinicocysteinate is a unique, patent-pending, next generation chromium complex. This new form of chromium has been studied in preliminary clinical research to be twice as effective as chromium picolinate in maintaining insulin function and healthy insulin levels trending toward normal range.*
Preliminary clinical research has shown that Zychrome™:
– Supports healthy insulin levels trending toward normal range.*
– Supports normal insulin function trending toward normal range.*
The suggested adult daily use is 400 mcg (elemental chromium as Zychrome™). Consumers interested in supplementing with Zychrome can refer to the manufacturer's suggested use printed on the finished product label and/or talk to their healthcare professional.
InterHealth launched Zychrome™ in May 2011. We are currently working with leading dietary supplement manufacturers in developing superior chromium supplements. Please check back soon for more details.
Manufacturers interested in using Zychrome in finished product applications, please contact InterHealth at 707-751-2800.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.